Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Sage Therapeutics is a biopharmaceutical company committed to developing novel the...
Sage Therapeutics is a biopharmaceutical compan...
Medpace is a scientifically-driven, global, full-service clinical contract researc...
Medpace is a scientifically-driven, global, ful...
Health Journal is a leader and influencer in health publishing in Virginia, USA an...
Health Journal is a leader and influencer in he...
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing ...
Clearside Biomedical, Inc. is a biopharmaceutic...
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics, Inc. is a clinical-stage b...
WinSanTorâs mission is simple-develop a drug that works. We recognize that there...
WinSanTorâs mission is simple-develop a drug ...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.